Agilent Technologies (NYSE:A) Price Target Raised to $190.00

Agilent Technologies (NYSE:A) had its price objective increased by Morgan Stanley from $175.00 to $190.00 in a research note released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Other equities research analysts have also issued research reports about the stock. The Goldman Sachs Group upped their target price on shares of Agilent Technologies from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Citigroup lifted their price target on Agilent Technologies from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. UBS Group initiated coverage on Agilent Technologies in a report on Wednesday, September 9th. They issued a “neutral” rating and a $165.00 price objective for the company. Bank of America boosted their price objective on Agilent Technologies from $155.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Finally, JPMorgan Chase & Co. increased their target price on Agilent Technologies from $180.00 to $190.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.65.

Agilent Technologies Trading Up 0.9%

A opened at $175.54 on Tuesday. The stock has a market capitalization of $49.49 billion, a PE ratio of 28.71, a P/E/G ratio of 2.65 and a beta of 1.21. The firm’s fifty day moving average price is $158.46 and its 200 day moving average price is $137.30. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.05 and a quick ratio of 1.56. Agilent Technologies has a 12-month low of $108.35 and a 12-month high of $177.05.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The firm’s revenue was up 8.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, research analysts expect that Agilent Technologies will post 6.20 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 28th. Stockholders of record on Tuesday, October 6th will be given a $0.2550 dividend. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.08%.

Insider Activity

In other news, Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $151.38, for a total value of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. The trade was a 11.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors have recently modified their holdings of the business. SHP Wealth Management bought a new position in Agilent Technologies in the fourth quarter worth about $26,000. Markowski Investments acquired a new position in Agilent Technologies in the second quarter valued at approximately $27,000. MV Capital Management Inc. acquired a new position in Agilent Technologies in the fourth quarter valued at approximately $28,000. Cedar Mountain Advisors LLC acquired a new position in Agilent Technologies in the first quarter valued at approximately $27,000. Finally, Keating Financial Advisory Services Inc. bought a new position in shares of Agilent Technologies during the second quarter valued at approximately $31,000.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Analyst price-target support: Morgan Stanley forecast meaningful appreciation for Agilent shares, while TD Cowen raised its price target. The revisions reinforce positive Wall Street sentiment and suggest analysts see additional upside despite the stock’s recent gains. Morgan Stanley Forecasts Strong Price Appreciation for Agilent Technologies Stock Agilent Technologies Stock Gets Price Target Bump from TD Cowen
• Positive Sentiment: Proscia acquisition expands AI capabilities: Agilent agreed to acquire pathology-software company Proscia for $240 million upfront, with the total consideration potentially reaching $270 million through milestones. The deal would strengthen Agilent’s position in AI-enabled digital pathology and scientific intelligence, adding a potentially faster-growing software component to its tools and diagnostics portfolio. Agilent Technologies to Acquire Proscia
• Positive Sentiment: Favorable market backdrop: A new industry report projects the global metabolomics market will expand at a 17.3% compound annual growth rate through 2030. Agilent is identified as one of the companies positioned to benefit as laboratories adopt AI-assisted diagnostics and advanced analytical technologies. Global Metabolomics Market Report 2026
• Neutral Sentiment: China expansion: Agilent plans to expand its capabilities in China, which could improve access to regional demand and support longer-term growth. However, execution, regulatory and geopolitical risks remain considerations for investors. Agilent to Expand Capabilities in China
• Negative Sentiment: Acquisition costs and integration risk: The Proscia transaction requires substantial capital and may create integration and milestone-payment risks before it contributes materially to earnings. With Agilent already trading at a premium valuation, investors may scrutinize the deal’s execution and return on investment.

About Agilent Technologies

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.